5 FDA Decisions for Primary Care to Know from March 2026

In March, the US Food and Drug Administration (FDA) issued several notable regulatory decisions spanning immunology, dermatology, diabetes management, and obesity care. The following list details 5 key updates for primary care, including approval of deucravacitinib for psoriatic arthritis, a first-in-class oral IL-23 receptor–targeted peptide for plaque psoriasis, a higher-dose semaglutide formulation for obesity, a once-weekly basal insulin, and a next-generation automated insulin delivery system.